Daewoong Pharmaceutical, "Diabetes New Drug Enblo Enters Four Major General Hospitals"

Passed by the Pharmacist Committee of the Four Major General Hospitals

Daewoong Pharmaceutical announced on the 10th that its new diabetes drug, Envlo (active ingredient: Inavogliflozin), a sodium-glucose co-transporter (SGLT)-2 inhibitor, has passed the pharmacy committees of major general hospitals including Samsung Seoul Hospital, Seoul National University Hospital, Asan Medical Center, and Severance Hospital.

Daewoong Pharmaceutical's new sodium-glucose co-transporter (SGLT)-2 inhibitor drug, Enblo tablets. [Photo by Daewoong Pharmaceutical]

Within just three months of its launch, Envlo has passed the pharmacy committees of more than 40 hospitals nationwide, including major hospitals in Seoul and leading university and general hospitals across the country. Daewoong Pharmaceutical explained that the rapid adoption of Envlo is due to its efficacy and safety being recognized by domestic medical professionals. A Daewoong Pharmaceutical representative stated, "We plan to expand Envlo’s prescription base to hospitals nationwide, and expect significant sales growth starting from the fourth quarter of this year."

Daewoong Pharmaceutical is also actively entering the global diabetes market. According to global research firm Linab Research, the global diabetes market is projected to reach $82.92 billion (approximately 108.5 trillion KRW) by 2027. In the first half of this year alone, Daewoong Pharmaceutical has submitted New Drug Application (NDA) dossiers to countries including Indonesia, the Philippines, Thailand, and Vietnam, accelerating its global expansion. The company plans to enter 15 countries by 2025 and 50 countries by 2030.

Envlo demonstrated equal or superior efficacy with only 0.3 mg, which is less than one-thirtieth the dose of existing SGLT-2 inhibitors. Through Phase 3 clinical trials conducted on patients with type 2 diabetes, Envlo proved its superiority in reducing glycated hemoglobin (HbA1c) and fasting blood glucose levels, as well as its safety compared to existing marketed drugs. Notably, in the approval clinical studies, Envlo showed effects such as weight loss, blood pressure reduction, improved lipid profiles, and enhanced insulin resistance. It also demonstrated superior blood glucose-lowering effects and improvement in proteinuria compared to drugs of the same class in type 2 diabetes patients with impaired renal function. This is expected to provide a new treatment option for patients with insufficient blood glucose control.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "Based on Daewoong Pharmaceutical’s accumulated research and development (R&D) capabilities and strong sales force established in the endocrinology market, we will achieve cumulative sales of 100 billion KRW for Envlo by 2026, its third year since launch. We will rapidly expand the prescription base through differentiated marketing based on excellent efficacy and accelerate overseas expansion."

This content was produced with the assistance of AI translation services.